Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2006-08-13 08:05:36 UTC |
---|
Update Date | 2022-03-07 02:49:20 UTC |
---|
HMDB ID | HMDB0003959 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | 19-Oxotestosterone |
---|
Description | 19-Oxotestosterone is catalyzed by Aromatase (EC 1.14.14.1),also called estrogen synthetase (a cytochrome P450 enzyme which catalyzes the formation of aromatic C18 estrogens from C19 androgens; it is symbolized CYP19) into oestrogens via sequential oxidations at the 19-methyl group. Biosynthesis of estrogens from C19 steroids is catalyzed by aromatase and its tissue-specific expression is determined at least in part by alternative use of tissue-specific promoters, which give rise to transcripts with unique 5-prime noncoding termini.(OMIM 107910 ). |
---|
Structure | [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C=O InChI=1S/C19H26O3/c1-18-8-7-16-14(15(18)4-5-17(18)22)3-2-12-10-13(21)6-9-19(12,16)11-20/h10-11,14-17,22H,2-9H2,1H3/t14-,15-,16-,17-,18-,19+/m0/s1 |
---|
Synonyms | Not Available |
---|
Chemical Formula | C19H26O3 |
---|
Average Molecular Weight | 302.4079 |
---|
Monoisotopic Molecular Weight | 302.188194698 |
---|
IUPAC Name | (1S,2S,10S,11S,14S,15S)-14-hydroxy-15-methyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-ene-2-carbaldehyde |
---|
Traditional Name | 19-oxotestosterone |
---|
CAS Registry Number | 4075-13-2 |
---|
SMILES | [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C=O |
---|
InChI Identifier | InChI=1S/C19H26O3/c1-18-8-7-16-14(15(18)4-5-17(18)22)3-2-12-10-13(21)6-9-19(12,16)11-20/h10-11,14-17,22H,2-9H2,1H3/t14-,15-,16-,17-,18-,19+/m0/s1 |
---|
InChI Key | TXNCGXATKOMEQC-KOUJMVCDSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Androstane steroids |
---|
Direct Parent | Androgens and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Androgen-skeleton
- 19-oxosteroid
- 3-oxo-delta-4-steroid
- 3-oxosteroid
- 17-hydroxysteroid
- Oxosteroid
- Hydroxysteroid
- Delta-4-steroid
- Cyclohexenone
- Cyclic alcohol
- Cyclic ketone
- Secondary alcohol
- Ketone
- Organic oxygen compound
- Carbonyl group
- Hydrocarbon derivative
- Aldehyde
- Organic oxide
- Organooxygen compound
- Alcohol
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 155 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.023 mg/mL at 25 °C | Not Available | LogP | 3.32 | HANSCH,C ET AL. (1995) |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
19-Oxotestosterone,1TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C=O)[C@@H]1CC[C@@H]2O[Si](C)(C)C | 2937.5 | Semi standard non polar | 33892256 | 19-Oxotestosterone,1TMS,isomer #2 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(O[Si](C)(C)C)=CC[C@@]43C=O)[C@@H]1CC[C@@H]2O | 2789.4 | Semi standard non polar | 33892256 | 19-Oxotestosterone,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(O[Si](C)(C)C)=CC[C@@]43C=O)[C@@H]1CC[C@@H]2O[Si](C)(C)C | 2804.2 | Semi standard non polar | 33892256 | 19-Oxotestosterone,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(O[Si](C)(C)C)=CC[C@@]43C=O)[C@@H]1CC[C@@H]2O[Si](C)(C)C | 2802.7 | Standard non polar | 33892256 | 19-Oxotestosterone,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CCC4=CC(O[Si](C)(C)C)=CC[C@@]43C=O)[C@@H]1CC[C@@H]2O[Si](C)(C)C | 3264.8 | Standard polar | 33892256 | 19-Oxotestosterone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C=O)[C@H]3CC[C@]12C | 3197.6 | Semi standard non polar | 33892256 | 19-Oxotestosterone,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(C=O)C(=C1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12 | 3050.5 | Semi standard non polar | 33892256 | 19-Oxotestosterone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(C=O)C(=C1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O[Si](C)(C)C(C)(C)C)CC[C@@H]12 | 3304.6 | Semi standard non polar | 33892256 | 19-Oxotestosterone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(C=O)C(=C1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O[Si](C)(C)C(C)(C)C)CC[C@@H]12 | 3279.8 | Standard non polar | 33892256 | 19-Oxotestosterone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@@]2(C=O)C(=C1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O[Si](C)(C)C(C)(C)C)CC[C@@H]12 | 3496.0 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - 19-Oxotestosterone GC-MS (Non-derivatized) - 70eV, Positive | splash10-00di-1190000000-38a46782f3a05e410638 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 19-Oxotestosterone GC-MS (1 TMS) - 70eV, Positive | splash10-0592-2169000000-be11c2989577a025bceb | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 19-Oxotestosterone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 19-Oxotestosterone 10V, Positive-QTOF | splash10-0f79-0095000000-f1b4c5073a1a349142cd | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 19-Oxotestosterone 20V, Positive-QTOF | splash10-0ktr-0191000000-787c331104e02697f82e | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 19-Oxotestosterone 40V, Positive-QTOF | splash10-052r-4290000000-c3ebd3f84fc5f2a0f1ad | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 19-Oxotestosterone 10V, Negative-QTOF | splash10-0udi-0039000000-fcbe7a10b70f243584ca | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 19-Oxotestosterone 20V, Negative-QTOF | splash10-0ue9-0098000000-88bd42d7a3c0ee3d7238 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 19-Oxotestosterone 40V, Negative-QTOF | splash10-05fs-0090000000-e5ab8ef14971dd3b053a | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 19-Oxotestosterone 10V, Positive-QTOF | splash10-0udi-0029000000-ab4e4333433d95463751 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 19-Oxotestosterone 20V, Positive-QTOF | splash10-0a4i-0190000000-58b8fdd5c28b55834da9 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 19-Oxotestosterone 40V, Positive-QTOF | splash10-0aba-0900000000-a07aa8a9e25f2da78867 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 19-Oxotestosterone 10V, Negative-QTOF | splash10-0udi-0019000000-e1aa2d5a1d9cdeff04e6 | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 19-Oxotestosterone 20V, Negative-QTOF | splash10-0pi0-0093000000-1d8018c21ff4c38691c5 | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 19-Oxotestosterone 40V, Negative-QTOF | splash10-0ab9-0290000000-794f96d5ceb67c29f858 | 2021-09-25 | Wishart Lab | View Spectrum |
|
---|
General References | - Schaap LA, Pluijm SM, Smit JH, van Schoor NM, Visser M, Gooren LJ, Lips P: The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clin Endocrinol (Oxf). 2005 Aug;63(2):152-60. [PubMed:16060908 ]
- Handelsman DJ: Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport. J Clin Endocrinol Metab. 2006 May;91(5):1646-53. Epub 2006 Feb 14. [PubMed:16478815 ]
- Huang I, Jones J, Khorram O: Human seminal plasma nitric oxide: correlation with sperm morphology and testosterone. Med Sci Monit. 2006 Mar;12(3):CR103-6. Epub 2006 Feb 23. [PubMed:16501419 ]
- Ahtiainen JP, Pakarinen A, Alen M, Kraemer WJ, Hakkinen K: Short vs. long rest period between the sets in hypertrophic resistance training: influence on muscle strength, size, and hormonal adaptations in trained men. J Strength Cond Res. 2005 Aug;19(3):572-82. [PubMed:16095405 ]
- Fejes I, Koloszar S, Szollosi J, Zavaczki Z, Pal A: Is semen quality affected by male body fat distribution? Andrologia. 2005 Oct;37(5):155-9. [PubMed:16266392 ]
- Jarow JP, Zirkin BR: The androgen microenvironment of the human testis and hormonal control of spermatogenesis. Ann N Y Acad Sci. 2005 Dec;1061:208-20. [PubMed:16467270 ]
- Klimek M, Pabian W, Tomaszewska B, Kolodziejczyk J: Levels of plasma ACTH in men from infertile couples. Neuro Endocrinol Lett. 2005 Aug;26(4):347-50. [PubMed:16136011 ]
- Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR: Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006 Aug 14-28;166(15):1660-5. [PubMed:16908801 ]
- Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM: Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006 Jun;91(6):1995-2010. Epub 2006 May 23. [PubMed:16720669 ]
- Jarow JP, Wright WW, Brown TR, Yan X, Zirkin BR: Bioactivity of androgens within the testes and serum of normal men. J Androl. 2005 May-Jun;26(3):343-8. [PubMed:15867001 ]
- Sipila S, Heikkinen E, Cheng S, Suominen H, Saari P, Kovanen V, Alen M, Rantanen T: Endogenous hormones, muscle strength, and risk of fall-related fractures in older women. J Gerontol A Biol Sci Med Sci. 2006 Jan;61(1):92-6. [PubMed:16456199 ]
- Mazer N, Fisher D, Fischer J, Cosgrove M, Bell D, Eilers B: Transfer of transdermally applied testosterone to clothing: a comparison of a testosterone patch versus a testosterone gel. J Sex Med. 2005 Mar;2(2):227-34. [PubMed:16422890 ]
- Pasqualotto FF, Lucon AM, de Goes PM, Sobreiro BP, Hallak J, Pasqualotto EB, Arap S: Relationship between the number of veins ligated in a varicocelectomy with testicular volume, hormonal levels and semen parameters outcome. J Assist Reprod Genet. 2005 Jun;22(6):245-9. [PubMed:16021853 ]
- Tan U: Testosterone and somatosensory evoked potentials from right and left posterior tibial nerves in right-handed young adults. Int J Neurosci. 1990 Dec;55(2-4):161-70. [PubMed:2084049 ]
- Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P: Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002 Nov 15;62(22):6538-44. [PubMed:12438248 ]
- Dicker A, Ryden M, Naslund E, Muehlen IE, Wiren M, Lafontan M, Arner P: Effect of testosterone on lipolysis in human pre-adipocytes from different fat depots. Diabetologia. 2004 Mar;47(3):420-428. doi: 10.1007/s00125-003-1324-0. Epub 2004 Jan 30. [PubMed:14752604 ]
- Ferrando AA, Sheffield-Moore M, Wolf SE, Herndon DN, Wolfe RR: Testosterone administration in severe burns ameliorates muscle catabolism. Crit Care Med. 2001 Oct;29(10):1936-42. [PubMed:11588456 ]
- Martinez-Riera A, Santolaria-Fernandez F, Gonzalez Reimers E, Milena A, Gomez-Sirvent JL, Rodriguez-Moreno F, Gonzalez-Martin I, Rodriguez-Rodriguez E: Alcoholic hypogonadism: hormonal response to clomiphene. Alcohol. 1995 Nov-Dec;12(6):581-7. [PubMed:8590623 ]
- Ebert T, Jockenhovel F, Morales A, Shabsigh R: The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel. Eur Urol. 2005 Feb;47(2):137-46. [PubMed:15661407 ]
- Lottrup G, Andersson AM, Leffers H, Mortensen GK, Toppari J, Skakkebaek NE, Main KM: Possible impact of phthalates on infant reproductive health. Int J Androl. 2006 Feb;29(1):172-80; discussion 181-5. [PubMed:16466537 ]
|
---|